ALKS

Alkermes reported strong third-quarter 2025 financial results and announced the proposed acquisition of Avadel Pharmaceuticals in October 2025. Alkermes presented at the Jefferies Global Healthcare Conference in London in November 2025. The company completed its acquisition of Avadel Pharmaceuticals plc in February 2026, strengthening its position in sleep medicine. Alkermes reported its fourth-quarter and full-year 2025 financial results and provided financial expectations for 2026 in February 2026. Alkermes initiated the Phase 3 clinical program for alixorexton in narcolepsy in Q1 2026. Alkermes reported stronger-than-expected first-quarter 2026 financial results in May 2026, leading to a stock price increase. Analyst ratings in May 2026 included Needham & Company LLC raising its price target for ALKS to $50.00, while Piper Sandler reduced its target to $43.00 in March 2026. Truist Financial upgraded shares to a "strong-buy" in March 2026, and Wells Fargo & Company boosted its price target to $43.00 in February 2026. Royal Bank of Canada decreased its price target to $45.00 in February 2026. In May 2026, EVP Craig C. Hopkinson and EVP David Joseph Gaffin sold shares of the company's stock. Richard Pops, the long-serving CEO, announced plans to step down in August 2026, with Blair Jackson planned as his replacement.